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Background: Statins are the most commonly prescribed drugs to reduce cardiometabolic risk. Besides the well-
known efficacy of such compounds in both preventing and treating cardiometabolic disorders, some patients ex-
perience statin-induced side effects. We hypothesize that the use of natural bergamot-derived polyphenols may
allow patients undergoing statin treatment to reduce effective doses while achieving target lipid values. The aim
of the present study is to investigate the occurrence of an enhanced effect of bergamot-derived polyphenolic frac-
tion (BPF) on rosuvastatin-induced hypolipidemic and vasoprotective response in patients withmixed hyperlip-
idemia.
Methods: A prospective, open-label, parallel group, placebo-controlled study on 77 patients with elevated serum
LDL-C and triglycerides was designed. Patients were randomly assigned to a control group receiving placebo
(n = 15), two groups receiving orally administered rosuvastatin (10 and 20 mg/daily for 30 days; n = 16 for
each group), a group receiving BPF alone orally (1000 mg/daily for 30 days; n = 15) and a group receiving
BPF (1000 mg/daily given orally) plus rosuvastatin (10 mg/daily for 30 days; n = 15).
Results: Both doses of rosuvastatin and BPF reduced total cholesterol, LDL-C, the LDL-C/HDL-C ratio and urinary
mevalonate in hyperlipidemic patients, compared to control group. The cholesterol lowering effect was accom-
panied by reductions of malondialdehyde, oxyLDL receptor LOX-1 and phosphoPKB, which are all biomarkers of
oxidative vascular damage, in peripheral polymorphonuclear cells.
Conclusions: Addition of BPF to rosuvastatin significantly enhanced rosuvastatin-induced effect on serum lipemic
profile compared to rosuvastatin alone. This lipid-lowering effect was associated with significant reductions of
biomarkers used for detecting oxidative vascular damage, suggesting a multi-action enhanced potential for
BPF in patients on statin therapy.© 2013 Published by Elsevier Ireland Ltd.1. Introduction
Dyslipidemia (or hypercholesterolemia) is an important risk factor
for the development of atherosclerosis and coronary artery disease, as
shown in several lipid intervention trials and prospective studiesepartment of Health Sciences,
Roccelletta di Borgia, 88100
5732; fax: +39 0961 369 4237.
eliability and freedom from bias
vier Ireland Ltd.[1]. Increased concentrations of low-density lipoprotein cholesterol
(LDL-C), total blood cholesterol (TC) and triglycerides (TG) comprise
the main pathogenic risk profile. Conditions of insulin resistance
such as impaired glucose tolerance or “prediabetes” are also associ-
ated with a high risk of cardiovascular disease (CVD) and are often
accompanied by low levels of high-density lipoprotein cholesterol
(HDL-C) [2]. The majority of therapeutic protocols rely on drugs
that belong to the “statin” family. Statins inhibit the activity of 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, which cata-
lyzes the rate-limiting step in mevalonate biosynthesis, a key interme-
diate in cholesterol metabolism. A meta-analysis of placebo-controlled
“standard dose” statin trials shows a reduction in cardiovascular mor-
tality averaging 20% and a decrease in major cardiovascular events by
approximately 25% [3]. Treatment with high-dose statins was shown
to reduce the morbidity by 36%, and a reduction of cardiovascular
141M. Gliozzi et al. / International Journal of Cardiology 170 (2013) 140–145events up to 40% [4]. Despite the significant clinical benefits pro-
vided by statins, many patients, in particular those with diabetes
or metabolic syndrome, do not achieve their recommended low-
density and high-density lipoprotein (LDL-C, HDL-C) cholesterol
target goals with statins alone [5]. Moreover, statins have been re-
ported to cause dose-related side effects, the more serious includ-
ing liver disease or severe myopathy, in up to 22% of patients
eligible for this therapeutic approach [6,7]. This limits the use of
statins and suggests the need for alternative and/or supplementary
therapeutic approaches.
Experimental and epidemiological evidence suggests that die-
tary polyphenols, in particular flavonoids, may play a role in ame-
liorating atherosclerosis, due to a pleiotropic anti-oxidative and
anti-inflammatory effect proposed as underlying mechanisms
[8–11]. In support of this hypothesis, it has been shown that certain
plant polyphenols, such as nobiletin and poncirin, inhibit mono-
cyte activation in vitro [9,12–17], and the enhancing effects of
such components may play a central role in this beneficial effect.
This observation provides the rationale for the optimal use of
appropriate, evidence-based phytochemicals as an adjunct to
treat hyperlipidemia with the aim of preventing cardiovascular
events.
Bergamot (Citrus bergamia) is an endemic plant growing in the
Calabrian region of Southern Italy with a unique profile of flavonoid
and glycosides present in its juice and albedo, such as neoeriocitrin,
neohesperidin, naringin, rutin, neodesmin, rhoifolin and poncirin.
Bergamot differs from other citrus fruits, not only for the composition,
but also for the particularly high content of flavonoids [18,19]. Some
of these flavonoids, such as naringin (which is also present in
grapefruit), have already been shown to be active in animal models
of atherosclerosis [20,21], while neoeriocitrin and rutin have been
found to exhibit a strong capacity to inhibit LDL oxidation [22]. Im-
portantly, bergamot juice is rich in 3-hydroxy-3-methylglutaryl
neohesperidosides of hesperetin (brutieridine) and naringenin
(melitidine) with an ability to inhibit HMG-CoA reductase [23].
These compounds are likely to contribute to the substantial
hypolipidemic effects of bergamot juice and to the vasoprotective
effects of bergamot oil derivatives in rats [24,25]. However, no clin-
ical study has been performed to date to evaluate the fruit's poten-
tial dyslipidemia-correcting properties.
Recently, we found that bergamot-derived polyphenolic fraction
(BPF), given orally both in animal models of diet-induced hyperlipid-
emia and in patients suffering from metabolic syndrome, produces a
significant and sustained reduction of serum cholesterol, triglycerides
and glycaemia [26]. This effect was accompanied by a significant im-
provement in vascular reactivity in patients with both hyperlipidemia
and elevated serum glucose, thus suggesting a potential protective
role for the use of BPF in patients with metabolic syndrome and
cardiometabolic risk.
Apart from these results, no evidence has been collected to date, on
the mechanism of action of bergamot-derived extract and on its poten-
tial benefit when used in comparison with statins in patients with met-
abolic syndrome.
To address these issues, we conducted a prospective, open-
label, parallel group, placebo-controlled study on patients with el-
evated serum LDL-C and triglycerides, to investigate the effect of
BPF in modulating serum lipidemic profile in patients suffering
from mixed hyperlipidemia, either untreated or treated with
rosuvastatin. The effect of rosuvastatin with BPF on the expression
of biomarkers of vascular oxidative stress and circulating cell via-
bility was also studied in these patients. In particular, we examined
the accumulation of malondialdehyde (MDA), a marker of lipid peroxi-
dation, the expression of LOX-1 receptor for oxidized LDL and protein
kinase B (PKB) phosphorylation in peripheral mononuclear cells
(PMC) in patients taking BPF alone or in combination with rosuvastatin
treatment.2. Materials and methods
2.1. Plant material
C. bergamia Risso & Poiteau fruits were collected from plants located in a range of
90 km from Bianco to Reggio Calabria, Italy.
2.2. Preparation of BPF
Bergamot juice was obtained from peeled-off fruits by squeezing. The juice was oil
fraction-depleted by stripping, clarified by ultra-filtration and loaded on to a suitable poly-
styrene resin column able to absorb polyphenol compounds ofmolecular weight between
300 and 600 Da (Mitsubishi). Polyphenol fractions were eluted by a 1 mM KOH solution.
The basic eluate was incubated at a rocking platform to reduce the fumocumarin content.
The shaking time was adjusted proportionally to the amount of fumocumarin contami-
nants. Next, the phytocomplex derived from the defurocoumarinization process was neu-
tralized by filtration on cationic resin at acidic pH. Finally it was vacuumdried andminced
to the desired particle size to obtain BPF powder. BPF powder was analyzed for flavonoid,
furocumarin and other polyphenol content. In addition, all toxicological analyses were
performed, including heavy metal, pesticide, phthalate and sinephrine content
which revealed the absence of known toxic compounds at significant levels (data
not shown). Standard microbiological test showed that the final BPF was free of my-
cotoxins and contaminating bacteria.
Finally, 500 mg aliquots of the BPF powder supplementedwith 50 mgof ascorbic acid
as antioxidant were encapsulated into suitable gelatin capsules by a semi-automatic gela-
tin encapsulation device employing an authorized pharmaceutical manufacturer (Plants,
Messina, Italy). All procedures have been performed according to GoodManufacture Prac-
tice (GMP) headlines of European Legislation.
The main flavonoids identified in BPF were neoeriocitrin (370 ppm), naringin
(520 ppm), and neohesperidin (310 ppm). Tablets containing 1000 mg of maltodestrin
supplemented with 50 mg ascorbic acid were used as placebo.
2.3. Patient selection and study design
A prospective, open-label, parallel group, placebo-controlled studywas designed.
We enrolled 77 patients suffering from mixed hypercholesterolemia (LDL-C levels of
N160 mg/dl, and triglycerides levels N225 mg/dl) from a primary care setting at the
Department of Cardiology of the IRCCS San Raffaele– Rome and at the Atherosclerosis
Prevention Ambulatory centre at the University of Rome “Tor Vergata” facility. Age,
gender, and body mass index were matched among all subjects. Patients were ran-
domly assigned to five groups, all following a low fat diet: a control group receiving
placebo (n = 15), two groups receiving oral rosuvastatin (10 and 20 mg/daily for
30 days; n = 16 for each group), a group receiving BPF alone orally (1000 mg/daily
for 30 days; n = 15) and a group receiving BPF (1000 mg/daily given orally) plus
rosuvastatin (10 mg/daily for 30 days; n = 15). In all groups, we determined the ef-
ficacy of each treatment by monitoring serum lipid profiles and urinary mevalonic
acid concentration (expressing inhibition of HMG-CoA reductase).
We excluded patients with overt liver disease, chronic renal failure, hypothyroidism,
myopathy, uncontrolled diabetes, severe hypertension, stroke, acute coronary events
within the preceding 30 days, coronary revascularization within the preceding 3 months,
or alcohol abuse. No patient was taking hormone replacement therapy or antioxidant vi-
tamin supplements during the 2 months preceding our study.
All the patients were given placebo, rosuvastatin, BPF alone or BPF plus rosuvastatin
before meals daily during a 30 day treatment period. A research nurse counted pills at
the end of treatment tomonitor compliance. Thepatientswere seen at leastweekly during
the study. To minimize side effects, we measured serum asparate aminotransferase, ala-
nine aminotransferase, creatine kinase, blood urea nitrogen, creatinine and blood cell
counts before and after therapy. Seven (7) patients taking placebo and 16 patients taking
BPF and/or rosuvastatin were smokers. Two (2) patients taking placebo, and 13 patients
taking BPF alone and/or rosuvastatin were also taking ACE inhibitors, angiotensin AT1 re-
ceptor blockers or beta adrenergic blockers to control blood pressure. No additional med-
ications including aspirin or nonsteroidal anti-inflammatory drugs were allowed during
the study period to avoid confounding effects of other drugs. Anti-hypertensive drugs
were withheld for ≥48 h before starting the study. Blood samples for assessing lipid pro-
file and 24 h urinary collectionwere performed at day 0 and after 30 day treatment in pla-
cebo, rosuvastatin and rosuvastatin/BPF-treated patients. At the same time, blood samples
were collected for assessing baseline values for blood cell counts, transaminases, creati-
nine blood levels and PMN separation and culturing.
All patients participating in the study signed an informed consent according to the
European Legislation and the protocol was previously submitted and approved by the Re-
gional Ethical Committee. In addition, the study protocol was performed according to the
ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by
the institution's human research committee.
2.4. Serum lipids
Total cholesterol, LDL-C, HDL-C and triglycerides in serum samples of patients were
determined colorimetrically and enzymatically using commercial assay kits (BioSystems
S.A., Barcelona, Spain).
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Twenty-four-hour urine samples were collected from each patient before and after
treatment with placebo, supplement and/or drugs. Total volume was recorded, and ali-
quots were frozen at −20 °C. Frozen urine samples were thawed and centrifuged at
1200 g for 30 min to remove solids. Urinary mevalonic acid (MVA) concentrations were
determined by means of a modification of the radioenzymatic isotope-dilution method
of Popjak (26). The intra-subject coefficient of variation was evaluated; 90% of all values
were found to lie within 35% of a single 24-h determination, whereas for two determina-
tions, the variation was 25%. The intra-assay coefficient of variation in each run was less
than 5%, whereas the inter-assay variation, based on the repeated analysis of the same
standard over a 2-year period, was 3.9% (25). The completeness of urine samples was de-
termined on the basis of subjects' records and their careful questioning; if these were
deemed incomplete, a repeated collection was obtained.2.6. Mononuclear cell isolation
Twenty milliliter of heparinised blood was diluted with the same volume of PBS and
carefully layered over 6 ml of Ficoll-Paque Plus (Amersham Biosciences, USA). The mix-
turewas centrifuged at 400 ×g for 40 min at 18–20 °C. The interface containing peripheral
blood mononuclear cells (PMNs) was collected and washed two times with PBS. This
preparation contained approximately 25%monocytes and 75% lymphocytes. Further puri-
fication of the monocytes from the PMNs fraction was accomplished by allowing the
monocytes to adhere to plastic. Using 25 cm2 culture dishes, PMNs were cultured for
45 min in RPMI 1640medium (with glutamax-I, Dutchmodification, Gibco BRL) contain-
ing 10% pooled human serum. The nonadhering lymphocytes were removed by washing
the culture dishes with PBS, after which the adherent monocytes were harvested. The re-
agents used for the isolation of monocytes contained no detectable endotoxins, as deter-
mined by the E-Toxate assay (Sigma, St. Louis, USA).2.7. Cell extracts and SDS-PAGE Western blotting
In order to study phosphor-PKB expression, PMNswere lysedwith ice-cold lysis buff-
er (20 mM Tris–HCl, pH 7.5; 150 mM NaCl; 2 mM EDTA; 2 mM EGTA; 1% Triton X-100;
1 nM okadaic acid, protease inhibitor cocktail - Sigma; phosphatase inhibitor cocktail —
Calbiochem), centrifuged at 10,000 ×g for 15 min at +4 °C. Alternatively, for LOX-1 de-
tection, PMNs were lysed with a different ice-cold lysis buffer (50 mM Tris pH 8,
150 mM NaCl, 1% Nonidet P-40; 2 mM Pefablock, 1 microM ml−1 Aprotinin, 10 microM
ml−1 Leupepeptin, 2 microM ml−1 Pepstatin A, trypsin inhibitor), centrifuged at
13,000 ×g for 30 min at +4 °C. Protein concentrations in supernatants were determined
by standard Bradford assay.
Lysates from each treatment (30 micrograms/lane) were resolved by 10% SDS–poly-
acrylamide gel electrophoresis and transferred to nitrocellulosemembranes. After incuba-
tion in blocking solution (4% dry nonfat milk, Sigma–Aldrich, St. Louis, MO), membranes
were incubated with anti-LOX-1 (1:10,000; gift from Professor T. Sawamura, Osaka,
Japan); anti-phospho-PKB (Ser 473) (1:2000; Cell Signaling Technology, USA). Mem-
branes were rinsed and then incubatedwith anti-mouse/anti-rabbit IgG antibody (GE
Healthcare, Buckinghamshire, England) for 1 h at room temperature. The specific
complex was detected by an enhanced chemiluminescence detection system (GE
Healthcare, Buckinghamshire, England) and relative intensities of protein bands
were analyzed by MSF-300G scanner (Microtek International, Inc., Hsinchu,
Taiwan). Membranes were stripped with restore western blot stripping reagent fol-
lowing the manufacturer's instructions (Pierce Chemical, Rockford, IL) and then
blocked (1 h at room temperature) with blocking solution and incubated with
mouse monoclonal anti-alpha-actin (1:1000 dilution; Sigma) or anti-PKB (1:2000;
Cell Signaling Technology, USA). After rinsing, the membranes were incubated with
antimouse horseradish peroxidase-conjugated secondary antibody (1:20,000 dilu-
tion; GE Healthcare, Buckinghamshire, England) and the specific complex was de-
tected by the enhanced chemiluminescence detection system (GE Healthcare,
Buckinghamshire, England). The relative intensities of protein bands were analyzed
by MSF-300G scanner.Table 1
Data on lipidemic serum profile of 77 patients undergoing 30 consecutive day treatment
with a daily dose of placebo, rosuvastatin (10 or 20 mg), BPF 1000 mg and BPF
1000 mg + rosuvastatin 10 mg, respectively. Data are expressed in mg/dl.
Total cholesterol LDL-C HDL-C Triglycerides
Basal levels 278 ± 4 191 ± 3 38 ± 2 238 ± 5
Placebo 275 ± 4 190 ± 2 38 ± 3 235 ± 5
Rosuvastatin 10 mg 195 ± 3⁎ 115 ± 4⁎ 42 ± 3⁎ 200 ± 4⁎
Rosuvastatin 20 mg 174 ± 4⁎ 87 ± 3⁎ 48 ± 3⁎ 202 ± 5⁎
BPF 1000 mg 191 ± 5⁎ 113 ± 4⁎ 45 ± 4⁎ 165 ± 3⁎
Rosuvastatin 10 mg + BPF
1000 mg
172 ± 3⁎ 90 ± 4⁎ 52 ± 4⁎ 152 ± 5⁎
⁎ P b 0.05 vs placebo.2.8. Malondialdehyde determinations
Malondialdehyde (MDA), a reliable biomarker used for studying lipid peroxidation,
was measured in PMNs of hyperlipemic patients either treated or not with BPF,
rosuvastatin or their combination. Levels of MDA were measured in PMNs isolated from
blood samples collected at the day 0 and 30 of treatment. Briefly, cells were homogenized
in potassium chloride (1.15%) and frozen in liquid nitrogen. Chloroform (2 ml) was then
added to each homogenate and then spun for 30 min.
The organic layer of the sample was removed and dried under nitrogen gas and re-
constituted with 100 μl of saline. MDA generation was evaluated by the assay of
thiobarbituric acid (TBA)-reacting compounds. The addition of a solution of 20 μl of sodi-
um dodecyl sulphate (SDS; 8.1%), 150 μl of 20% acetic acid solution (pH3.5), 150 μl l of
0.8% TBA and 400 μl l of distilled water, produced a chromogenic product which was
extracted in n-butanol and pyridine. Then, the organic layer was removed andMDA levels
read at 532 nm and expressed as nmol MDA/g prot.2.9. Statistical analyses
Bartlett's testwas performedoneach set of data to ensure that varianceof the setswas
homogenous. In case of homogenous set of data, ANOVAwas performed to determine the
treatment effects, and Dunnett's test was employed as appropriate. In case of heteroge-
nous data, F test was carried out to determine which pairs of groups were heterogenous.
This was followed by Student's t tests.3. Results
3.1. The effect of BPF and/or plus rosuvastatin on serum lipids of patients
with mixed hyperlipidemia
Oral administration of BPF (1000 mg/daily for 30 consecutive days;
n = 15) in patients suffering from mixed hyperlipidemia significantly
reduced total cholesterol, LDL-C, triglyceride and enhanced HDL-C
levels (Table 1). No change in serum total cholesterol, LDL-C, HDL-C
and triglycerides was found in the group of patients receiving placebo
compared to basal lipidemic profile (Table 1).
Neither symptoms nor hematochemical signs of toxicity were found
in any patients undergoing BPF and/or placebo administration (not
shown). In 2 patients treated with BPF/daily, a moderate gastric pyrosis
was observed. However, none of the patients taking BPF interrupted the
treatment.
Administration of rosuvastatin (10 and 20 mg/daily; n = 16 for
each group; Table 1) produced a significant (P b 0.05) reduction of
total cholesterol and LDL-C compared to placebo. Minimal and insignif-
icant changes in triglycerides occurred after treating patients with
rosuvastatin at both doses daily. Furthermore, an elevation of HDL-C
was found.
Association of BPF (1000 mg/daily) with the lower dose of
rosuvastatin (10 mg) for 30 consecutive days produced a significant
enhancement of the hypolipidemic effect of rosuvastatin compared
with the effect of rosuvastatin alone (Table 1). Indeed, the lower dose
of rosuvastatin (10 mg/daily) when given in combination with a single
oral dose of BPF (1000 mg/daily) produced a significant decrease on
total cholesterol and LDL-C serum levels in hyperlipidemic patients
when compared to rosuvastatin alone, an effect which was nearly the
same than the one produced by 20 mg of rosuvastatin. In addition, tri-
glycerides were reduced by 36 ± 5% and HDL-C was increased by
37 ± 2%, an effect which was significantly higher while compared to
the use of rosuvastatin alone.3.2. The effect of BPF and/or rosuvastatin on urinary mevalonate (MVA)
Twenty-four-hour urinary MVA excretion in hyperlipidemic pa-
tients undergoing BPF (1000 mg/daily for 30 days), rosuvastatin (10
and 20 mg/daily for 30 days) or combination of BPF (1000 mg) plus
rosuvastatin was significantly decreased (P N0.05) in all groups com-
pared to placebo (Fig. 1). Interestingly, the group of patients receiving
both BPF and the low concentration of rosuvastatin, showed that BPF
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Fig. 1. The graph showsmean values for 24 h urinarymevalonic acid excretion in patients
at 0 time (black columns) and after 30 days (grey columns) of oral treatment with place-
bo, BPF (1000 mg/daily), rosuvastatin (10 and 20 mg/daily) and rosuvastatin (10 mg/
daily plus BPF 1000 mg/daily). Error bars show the standard deviation (S.D.). * - indicates
a statistically significant change compared to the placebo group at P b0.05.
Fig. 3. Representative western blotting analysis showing the expression of oxyLDL recep-
tor LOX-1 in peripheral PMNs of patients with mixed hyperlipidemia patients after
30 days of oral treatment with placebo, BPF (1000 mg/daily), rosuvastatin (10 and
20 mg/daily) and rosuvastatin (10 mg/daily plus BPF 1000 mg/daily).
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CoA reductase.
3.3. The effect of BPF and/or rosuvastatin on MDA, phosphoPKB and LOX-1
levels in peripheral PMNs of hyperlipemic patients
Peripheral PMNswere isolated from the peripheral blood of each pa-
tient entering the study and re-suspended into Krebs buffer. The levels
ofMDA (amarker of lipid peroxidation) and the expression of LOX-1 re-
ceptor for oxyLDL were detected in peripheral PMNs before and at the
end of the treatment with BPF and rosuvastatin given alone or in
combination.
The basal levels of MDA and the expression of LOX-1 have been pre-
viously found elevated in patients with hyperlipidemia compared to a
group of normolipidemic patients (n = 15; not shown). Administration
of BPF (1000 mg/daily for 30 days), rosuvastatin (10 and 20 mg/daily
for 30 days) or a combination of both (1000 mgplus 10 mg, respective-
ly) significantly decreased both MDA levels and LOX-1 expression in
PMNs of patients withmixed hyperlipidemia (Figs. 2 and 3). In particu-
lar, the effect of BPF produced a further enhancement of rosuvastatin
antioxidant effect (as shown by decreasedMDA levels) and a significant
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Fig. 2. The graph showsmean values formalondialdehyde (lipid peroxidation) in PMNs of
patients after 30 days of oral treatment with placebo, BPF (1000 mg/daily), rosuvastatin
(10 and 20 mg/daily) and rosuvastatin (10 mg/daily plus BPF 1000 mg/daily). Error bars
show the standard deviation (S.D.). * - indicates a statistically significant change compared
to the placebo group at P b0.05.effects significantly correlated with vasoprotective properties of statins
in patients with cardiometabolic risk. The effect of BPF in combination
with rosuvastatin also resulted in an enhanced expression of PKB levels
in PMNs of hyperlipemic patients (Fig. 4). In particular, we found an en-
hanced phosphorylation of PKB, an effect which accounts for a better
vasoprotection against factors supporting smooth muscle cell prolifera-
tion and vascular damage.
4. Discussion
Our data show that bergamot extract rich in polyphenols (BPF),
given orally for 30 consecutive days allows the reduction of daily dose
of rosuvastatin while achieving target lipid values in patients with
mixed dyslipidemia (elevated serum LDL-Cwith hypertriglyceridemia).
This effectwas characterized by a reduction of both total cholesterol and
LDL-C and amplified the increase of HDL-C produced by rosuvastatin
alone. This enhancement of statin-induced effects suggests a potential
benefit in the reduction of cardiometabolic risk. Furthermore, the reduc-
tion of serum cholesterol in patients taking both BPF and rosuvastatin is
accompanied by a significant reduction in triglyceride levels, an effect
which has not been found with rosuvastatin alone, thus suggesting an
additive role of BPF in statin-induced hypolipidemic response.
These data are in accordance with previous evidence showing that
bergamot derivatives possess antilipidemic and vasoprotective effects
both in rat models of hyperlipidemia and vascular disease and in hyper-
lipidemic patients [24–26]. In addition, there is a significant additiveFig. 4. Representative western blotting analysis showing the state of phosphorylation of
PKB (phosphoPKB) in peripheral PMNs of patients withmixed hyperlipidemia patients ei-
ther untreated (CTRL) as well as after 30 days of oral treatment with placebo, BPF
(1000 mg/daily), rosuvastatin (10 and 20 mg/daily) and rosuvastatin (10 mg/daily plus
BPF 1000 mg/daily).
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fect consistent with the further reduction seen in urinary MVA as de-
tected in patients after treatment with both BPF and lower doses of
rosuvastatin.
Beyond the clear antilipemic/hypoglycemic response which follows
30 day treatment with BPF in patients, the mechanism of action of this
bergamot derivative remains to be elucidated. Previous data showed
that non-nutritive constituents of Citrus family fruits, such as pectin
and flavonoids found in peel extracts, cause lowering of serum and/or
tissue cholesterol levels by modulating hepatic HMG-CoA levels, possi-
bly by binding bile acids and increasing the turnover rate of blood and
liver cholesterol [27–31]. Since BPF showed enhancement in the excre-
tion of fecal sterols in rats [26], such a mechanism may contribute to
both the hypolipidemic and hypoglycemic response of bergamot deriv-
atives. However, a major contribution to the hypolipidemic response
found in patients undergoing BPF treatment seems to be related to the
modulatory properties in the flavonone glycoside component of the
bergamot juice extract, in particular naringin and neo-hesperidin.
Indeed, evidence exists that dietary hesperetin reduces hepatic TG
accumulation associated with a reduced activity of TG synthetic en-
zyme, PAP [32]. In addition, in vitro studies suggest that hesperetin
may, in part, reduce apoB levels [33]. Together with an enhanced ex-
pression of the LDL receptor, these mechanisms may explain, at least
in part, the hypocholesterolemic properties of the citrus flavonoids
[34] and of BPF, as found in our experiments.
Furthermore, naringenin has been shown to act at multiple levels in
regulating lipid metabolism in patients [35]. Moreover, naringin was
found to reduce both VLDL-derived and endogenously synthesized
fatty acids, preventing muscle triglyceride accumulation and, finally,
improving overall insulin sensitivity and glucose tolerance [36].
The effect of both naringin and hesperidin seems also to involve di-
rect inhibition of the HMG-CoA reductase enzyme system [37]. This is
confirmed by our data in which MVA, the end product of HMG-CoA
reductase activity, was reduced by treatment with BPF. Furthermore,
ACAT activities as a result of naringin supplementation could account
for the decrease of fecal neutral sterols [37]. In addition, BPF seems to
contain high concentration of buteridine and melitidine [38], two
flavonone derivatives shown to selectively inhibit HMG-CoA reduc-
tase, and this may well explain the potency of BPF in reducing cho-
lesterol levels [23].
Our data also show an additive vaso-protective effect of BPF when
given associated with rosuvastatin, an effect probably due to the an-
tioxidant properties of bergamot polyphenols. This is shown by the
enhanced reduction of both LOX-1 and phosphorylation of PKB in
PMNs of patients undergoing rosuvastatin treatment in combination
with BPF and by simultaneous reduction of MDA, a biomarker of lipid
peroxidation. This confirms previous studies showing that BPF given
in hyperlipemic patients, improves reactive vasodilatation [26]. Fur-
thermore, we recently showed that expression of LOX-1 receptor is
associated with smooth cell proliferation in injured blood vessel, an
effect counteracted by bergamot extract [25] as well as by exogenous
antioxidants [39]. Finally, BPF contributed to the statin-induced in-
crease of PKB phosphorylation. This may be relevant due to the evi-
dence that PKB is a member of the second-messenger family that
regulates the sub-family of protein kinases implicated in signaling
downstream of tyrosine kinases and PI3-kinase. When phopshorylated,
PKB leads to vasoprotection, an effect which is confirmed by evidence
that statins are known to produce protection against vascular athero-
genic injury also via PKB phosphorylation in response to mitogens and
survival factors [40]. Thus, exogenous supply of natural antioxidants,
such as bergamot-derived polyphenols, highlighted the modulation of
peripheral biomarkers of cardiometabolic risk induced by rosuvastatin
showing an additive vasoprotective potential for this natural extract
in patients with hyperlipemia.
In conclusion, our data show that BPF enhances the effect of
rosuvastatin in normalizing the serum lipemic profile. Clinically, thismay allow a reduction in daily rosuvastatin doses for maintaining pa-
tients to target levels of cholesterol. In addition, BPF contributes to the
reduction in oxidative processes found in hyperlipemic patients, thus
suggesting a potential vasoprotective benefit of using such natural poly-
phenols in hyperlipemic patients undergoing statin treatment.
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